The study, which was published June 1, 2016 in Nature Communications, showed the compound significantly improved several aspects of cells taken directly from patients with spinocerebellar ataxia type 10 (SCA10), a form of spinocerebellar ataxia.
«More than 30 diseases, all of them incurable, are caused by RNA repeats," said TSRI Professor Matthew Disney, who led the study. «By a thorough basic science investigation, we identified small molecules that target RNA base pairs precisely. We then leveraged this information to design the first drug candidate that binds to
SCA10 is caused by what is called a pentanucleotide repeat (a genetic sequence of five nucleotides repeated many more times than normal) affecting the mitochondria, the cell’s energy source. The new drug candidate, known as
«The potent bioactivity of
The Disney group has developed new tools to identify optimal interactions between RNA structures and drug candidates targeting them. A database of these interactions has already been used to design several small molecule drug candidates.
«We are in the process of developing tools that allow one to design small molecules to target any RNA structural motif in a complex cellular environment. That environment can contain millions of other RNAs. In this study,
Pathogenic RNA repeats contribute to disorders including Huntington’s disease, fragile
In addition to Disney and Yang, other authors of the study, «Studying Small Molecule Recognition of RNA Base Pairs Enables Design of a Bioactive Small Molecule that Targets r(AUUCU) Repeats in Spinocerebellar Ataxia 10," are Mark Southern of TSRI and Rui Gao and Partha S. Sarkar of the University of Texas Medical Branch.
The work was supported by the National Institutes of Health (R01 GM097455 and DP1NS096898), the John Sealy Memorial Endowment Fund for Biomedical Research, the FRAXA Research Foundation and TSRI.
Source: http://www.scripps.edu/news/press/2016/20160601disney.html